AdCab's Scientific Lead, Dr. Firas Hamdan, was voted best pitch by the audience at the Finnish Biotech and Investor Summit — his first pitching competition. Competing alongside ten other biotech companies, he presented AdCab's dual-action oncolytic immunotherapy to an audience of investors and life science stakeholders.
The event, organized by Tesi, Innovestor, and the Finnish Drug Discovery Center (Suomen Lääkekehityskeskus Oy), brought together innovators and investors from across the Finnish life science ecosystem. The recognition marks an important milestone for AdCab as we advance toward clinical development.